REVA Medical to Hold Briefing Call on Financial Results for 2012 and Presentation at Cowen Health Care Conference
28 February 2013 - 2:08PM
REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") will hold a
conference call to discuss the Company's financial results through
December 31, 2012 and its business outlook. Robert Stockman,
Chairman and CEO, will host the call.
The call is scheduled for 2:00 p.m. US PST on Tuesday, March 5,
2013 (which is 9:00 a.m. AEDT on Wednesday, 6 March 2013) and may
be accessed within the United States by dialing 1-877-312-5413 five
minutes prior to the call. Callers in Australia may access the call
by dialing (02) 8223 9876. If you are asked to provide an access
code, please spell out the word "REVA" to the operator and you will
be connected promptly. A replay of the audiocast will be available
on the Company's website at www.revamedical.com following the
call.
Mr. Stockman is also scheduled to present at the Cowen and
Company 33rd Annual Health Care Conference at 11:20 a.m. US EST on
Wednesday, March 6, 2013. The conference is being held March 4th
through 6th at the Boston Marriott Copley Place, in Boston,
Massachusetts. A copy of the presentation materials will be
available on REVA's website at www.revamedical.com shortly before
the presentation.
About REVA
REVA is a development stage medical device company incorporated
in Delaware, USA, that is focused on the development and eventual
commercialization of its proprietary bioresorbable stent products.
The ReZolveĀ® product family, which is in a clinical study phase,
combines REVA's proprietary stent design with a proprietary polymer
that is metabolized and cleared from the body. REVA's anticipated
commercial product, the ReZolve2 scaffold, is designed to offer
full x-ray visibility, clinically relevant sizing, and a controlled
and safe resorption rate. In addition, by early encapsulation of
the stent in the artery tissue coupled with the loss of scaffold
structure over time, the ReZolve2 scaffold may reduce the incidence
of late forming blood clots or otherwise reduce long-term disease
progression, potential benefits of bioresorbable scaffolds that
have yet to be proven. REVA will require clinical results and
regulatory approval before it can begin selling the ReZolve2
scaffold.
The REVA Medical, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8505
CONTACT: United States
Investor and Media Enquiries:
Cheryl Liberatore
Director, Investor Relations and Marketing
REVA Medical, Inc.
+1 858 966-3045
Australia
Investor Enquiries:
Kim Jacobs or Alan Taylor
Inteq Limited
+61 2 9231 3322
Media Enquiries:
Haley Price or Rebecca Wilson
Buchan Consulting
+61 3 9866 4722
Reva Medical (ASX:RVA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Reva Medical (ASX:RVA)
Historical Stock Chart
From Oct 2023 to Oct 2024